Tabernanthalog

Clinical data
Other names	TBG; DLX-007; DLX007
Routes of administration	Oral[1]
Drug class	Non-selectiveserotonin receptor modulator; Non-hallucinogenicserotonin5-HT2A receptorpartial agonist
ATC code	None
Identifiers
IUPAC name 8-methoxy-3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indole
CAS Number	2483829-59-8
PubChemCID	146026994
ChemSpider	114959868
CompTox Dashboard(EPA)	DTXSID301336754
Chemical and physical data
Formula	C14H18N2O
Molar mass	230.311 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1CCC2=C(CC1)NC3=C2C=CC(=C3)OC
InChI InChI=1S/C14H18N2O/c1-16-7-5-12-11-4-3-10(17-2)9-14(11)15-13(12)6-8-16/h3-4,9,15H,5-8H2,1-2H3 Key:FNGNYGCPNKZYOG-UHFFFAOYSA-N

Tabernanthalog (TBG; developmental code nameDLX-007) is anon-selectiveserotonin receptor modulator and putatively non-psychedelicpsychoplastogen of theibogalog group related to theiboga alkaloidtabernanthine but with a simplifiedchemical structure.^[2][3] It was developed byDavid E. Olson and colleagues at theUniversity of California, Davis.^[3] The drug is being developed byDelix Therapeutics as a potentialpharmaceutical drug for treatment ofneuropsychiatric disorders.^[1][4]

There have been informalanecdotal reports of the effects of tabernanthalog.^[5][6][7] It is said to bepsychoactive and mildlyhallucinogenic at sufficiently high doses and to have a longduration.^[6] Its hallucinogenic effects have been said to be similar to but weaker than those ofserotonergic psychedelics.^[6][7] There were also reports ofside effects likenausea,dizziness,stomach discomfort, anddiarrhea.^[6][7] However, it is unclear whether the reports have always employed actual tabernanthalog.^[6]

Tabernanthalog is anon-selective and non-psychedelicserotonin receptor modulator, including acting as anagonist of theserotonin5-HT_1B,5-HT_1F,5-HT_2A,5-HT_2C, and5-HT₆ receptors and as an agonist orantagonist of theserotonin5-HT_2B receptor.^[3][8][10] It also shows significant binding to theserotonin transporter (SERT) (acting as aserotonin reuptake inhibitor), theα_2A-adrenergic receptor, andmonoamine oxidase A (MAO-A).^[3] In contrast toiboga alkaloids likeibogaine andnoribogaine, tabernanthalog showed negligible interactions withopioid receptors, theNMDA receptor, and certainnicotinic acetylcholine receptors.^[3] However, in subsequent research, it weakly inhibited certain nicotinic acetylcholine receptors, as well as, to a much lesser extent, theGABA_A receptor.^[12] Tabernanthalog was found to be 100-fold lesspotent at thehERGantitarget compared to ibogaine, and hence is thought to have a much lower potential forcardiotoxicity.^[3]

Tabernanthalog did not produce thehead-twitch response, a behavioral proxy ofpsychedelic effects, in rodents, and hence appears to be non-hallucinogenic.^[3] However, it was found to promote structuralneuroplasticity (i.e., to act as apsychoplastogen), reducedrug-seeking behavior, and produceantidepressant-like effects.^{[3][13][14][15]} It has also been shown that it reduces motivation for heroin andalcohol in rodents.^[15]

Tabernanthalog was first described in thescientific literature byDavid E. Olson and colleagues at theUniversity of California, Davis in January 2021.^[3][16]

Tabernanthalog has been known to be sold online byresearch chemical vendors for purposes such as "nootropic" use.^[6]

Tabernanthalog is under development for the treatment ofcentral nervous system disorders (CNS disorders).^[1][17] It is being developed byDelix Therapeutics.^[1][17] As of May 2025, no recent development has been reported.^[1] It had reached thepreclinical research stage of development.^[1][17] Aphase 1clinical trial was being planned for the first half of 2023.^[1] Delix Therapeutics also partnered withNational Institute on Drug Abuse (NIDA) to evaluate tabernanthalog for the treatment ofsubstance-related disorders in December 2021.^[1]

• Ibogalog
• Tabernanthine
• Catharanthalog
• DLX-159
• Ibogainalog
• Ibogaminalog (DM-506)
• Noribogainalog
• PNU-22394
• Non-hallucinogenic 5-HT_2A receptor agonist

• Tabernanthalog - Isomer Design

• Drugs not assigned an ATC code
• 5-HT1B agonists
• 5-HT1F agonists
• 5-HT2B agonists
• 5-HT2B antagonists
• 5-HT2C agonists
• 5-HT6 agonists
• Adrenergic receptor modulators
• N,N-Dialkyltryptamines
• Ibogalogs
• Methoxy compounds
• Nicotinic antagonists
• Non-hallucinogenic 5-HT2A receptor agonists
• Psychoplastogens
• Serotonin reuptake inhibitors

• Use dmy dates from September 2025
• Articles with short description
• Short description is different from Wikidata
• Articles without EBI source
• Chemical pages without DrugBank identifier
• Articles without KEGG source
• Articles without UNII source
• Drugs with no legal status
• Articles containing unverified chemical infoboxes